Denali Therapeutics’ (DNLI) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report report published on Monday morning,Benzinga reports. They currently have a $39.00 price objective on the stock.

A number of other research firms also recently weighed in on DNLI. Wolfe Research initiated coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Monday, April 20th. Leerink Partners decreased their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Robert W. Baird boosted their target price on Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, The Goldman Sachs Group boosted their target price on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Denali Therapeutics Trading Up 1.7%

NASDAQ:DNLI opened at $19.80 on Monday. The firm has a market cap of $3.14 billion, a P/E ratio of -6.87 and a beta of 0.99. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock’s 50 day simple moving average is $20.04 and its 200-day simple moving average is $18.95. Denali Therapeutics has a 12-month low of $12.58 and a 12-month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the business posted ($0.78) earnings per share. Equities analysts anticipate that Denali Therapeutics will post -2.77 EPS for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new position in Denali Therapeutics in the second quarter valued at $26,000. Johnson Financial Group Inc. acquired a new position in Denali Therapeutics in the third quarter valued at $29,000. State of Wyoming acquired a new position in Denali Therapeutics in the second quarter valued at $29,000. Fifth Third Bancorp acquired a new position in Denali Therapeutics in the first quarter valued at $55,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Denali Therapeutics in the fourth quarter valued at $57,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics News Summary

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Denali Therapeutics and maintained a $42 price target, signaling continued confidence in the company’s longer-term pipeline and valuation potential.
• Positive Sentiment: The firm also raised earnings estimates across multiple periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029, and FY2030, which can support investor sentiment if the market views the revisions as evidence of improving outlook.
• Positive Sentiment: Denali also presented at the Bank of America Global Healthcare Conference 2026, which may have helped keep attention on the stock by giving investors an update on the company’s strategy and development pipeline. Article Title
• Neutral Sentiment: BTIG Research also reportedly initiated or maintained a Buy view on DNLI, adding to the generally constructive analyst backdrop. Article Title
• Negative Sentiment: Despite the upbeat ratings, Denali remains unprofitable, with analysts still expecting negative EPS across the next several years, which may limit upside if investors focus on cash burn and commercialization risk.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.